Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-4000 plus gemcitabine versus placebo plus gemcitabine in resected Ras-mutant pancreatic cancer
2007-005386-35Phase 2Completed
- Sponsor
- GlobeImmune
- Start
- Jul 2008
- Modality
- Small Molecules, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GI-4000, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by GlobeImmune. Started Jul 2008; status: completed.
02
Drugs
GI-4000gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2007-005386-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005386-35.